Eli Lilly to seek approval next year for retatrutide after strong Phase 3 obesity results
read at Endpoints ↗ApprovalPositive
Eli Lilly announced that its experimental obesity drug retatrutide will be submitted to regulators for approval early next year.
The decision follows recent Phase 3 trial data that showed the drug produced the greatest weight loss among late-stage candidates, marking a second set of positive Phase 3 outcomes for the triple-agonist.
Lilly said the filing timeline reflects confidence in the data and aims to bring the therapy to patients seeking effective obesity treatment.
source
This writeup was produced by pharmadog from original reporting by Endpoints.
Original headline: “Lilly's triple agonist heads to regulators after two more Phase 3 obesity wins”
read at Endpoints ↗86 words · retrieved Jul 23
comments(0)
5-min edit window · permanent after that